18 results
Search Results
2. Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England: Cost-Utility Analysis of WCD in England
3. Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis: Cost-effectiveness of Semaglutide versus Liraglutide for Obesity
4. Pricing for Multi-Indication Drugs in the Italian Regulatory Context: Pricing for Multi-Indication Drugs
5. Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany: Complications and HCRU of SCD with Recurrent VOCs and TDT
6. Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis: Sepsis Care Economic Analysis
7. CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks: Analysis of Speaker Remarks in CMS’s 2023 Patient-Focused Listening Sessions
8. Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment: Costs of Adverse Events in aRCC
9. Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years: Cost-Effectiveness of Three DES
10. Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy: Burden of TDT and SCD with Recurrent VOCs in Italy
11. Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing: System Dynamics Modelling for Integrating MCED Tests with Standard Screening
12. Costs of Illness for Huntington’s Disease: A Systematic Review: Review of Costs in HD
13. Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA: Cost-Effectiveness of Fruquintinib in Metastatic Colorectal Cancer
14. Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study: Cost Effectiveness of Vedolizumab as First-Line Biologic in Inflammatory Bowel Diseases
15. Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients
16. Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis: Time Trade-Off Analysis of Health State Utility Values for IgAN
17. Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland: Healthcare Resource Use and Costs of Multiple Myeloma in Finland
18. Acknowledgement to Referees: Acknowledgement to Referees
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.